CVS Caremark settlement could save people billions on prescriptions

A settlement involving CVS Caremark could potentially save consumers billions of dollars on prescription costs. The legal action follows allegations that the PBM intentionally preferred more expensive versions of insulin to increase its own rebates. This practice reportedly led to higher prices for a lifesaving drug, impacting patients' access to affordable medication. The resolution of these claims aims to address the pricing discrepancies caused by the PBM's preference for higher-cost insulin options over cheaper alternatives.